Curative Effect of EGFR-TKIs with Anti-angiogenic Drugs as the Treatment for Patients with Advanced EGFR-mutant Non-small Cell Lung Cancer:a Meta-analysis
BackgroundAcquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) will eventually occur in almost all advanced EGFR-mutant non-small cell lung cancer (EGFR-mutant NSCLC) patients although the therapy has been a standard treatment for such patients. But EGFR-TKI...
Main Author: | LI Yong, LONG Yong, ZHAO Chong, ZHANG Guanqing, SU Yanhe |
---|---|
Format: | Article |
Language: | zho |
Published: |
Chinese General Practice Publishing House Co., Ltd
2022-03-01
|
Series: | Zhongguo quanke yixue |
Subjects: | |
Online Access: | https://www.chinagp.net/fileup/1007-9572/PDF/yx2021123102.pdf |
Similar Items
-
Detection and Evaluation of EGFR Mutation Status in Serum of Patients with Advanced Non-small Cell Lung Cancer Treated with EGFR-TKIs
by: Ling MA, et al.
Published: (2013-06-01) -
Influence of PD‐L1 expression on the efficacy of EGFR‐TKIs in EGFR‐mutant non‐small cell lung cancer
by: Si‐Yu Lei, et al.
Published: (2023-08-01) -
Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
by: Wen M, et al.
Published: (2018-11-01) -
Investigating the Efficacy of EGFR-TKIs and Anti-VEGFR Combination in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis
by: Prashant Sakharkar, et al.
Published: (2024-03-01) -
Research Progress of New Generation EGFR-TKIs after Third-generation
by: Yuanyuan LIU, et al.
Published: (2020-11-01)